The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma

Cancer

Volumn 82, Issue 6, 1998, Pages 1037-1048

  Bonner, James A ^a,g   McGinnis, William L ^b   Stella, Phillip J ^c   Marschke Jr , Robert F ^a   Sloan, Jeff A ^a   Shaw, Edward G ^a   Mailliard, James A ^d   Creagan, Edward T ^a   Ahuja, Rajender K ^e   Johnson, Patricia A ^f  

^a MAYO CLINIC   (United States)

^b Iowa Oncology Research Association CCOP   (United States)

^c Ann Arbor Regional CCOP   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e Toledo Community Hospital Oncology Program CCOP   (United States)

^f Carle Cancer Center CCOP   (United States)

^g Department of Radiation Oncology ^*  (United States)

Author keywords

Hyperfractionation; Nonsmall cell lung carcinoma; Thoracic radiotherapy

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032521282     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980315)82:6<1037::AID-CNCR5>3.0.CO;2-B     Document Type: Article

References (38)

1. Wolf J, Patno ME, Roswit B, D'Esopo N. Controlled study of survival of patients with clinically inoperable lung cancer treated with radiation therapy. Am J Med 1966;40:360-7.
2. Roswit B, Patno ME, Rapp R, Veinbergs A, Feder B, Stuhlbarg J, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968;90:688-97.
3. Perez CA, Stanley K, Rubin P, Kramer S, Brady L, Perez-Tamayo R, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45:2744-53.
4. Cox JD. Large-dose fractionation (hypofractionation). Cancer 1985;55(Suppl 9):2105-11.
5. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539-47.
6. Cox JD. Fractionation: a paradigm for clinical research in radiation oncology. Int J Radiat Oncol Biol Phys 1987;13: 1271-81.
7. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.6 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990;8:1543-55.
8. Cox JD, Pajak TF, Herskovic A, Urtasun R, Podolsky WJ, Seydel HG. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08. Am J Clin Oncol 1991;14:280-4.
9. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990;113:33-8.
10. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323: 940-5.
11. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
12. Beahrs OH, Henson D, Hutter RVP, Kennedy BJ, editors. Manual for staging of cancer. 4th edition. American Joint Committee on Cancer. Philadelphia: J. B. Lippincott, 1992: 70-3.
13. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-23.
14. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
15. Reddy S, Lee MS, Bonomi P, Taylor SG IV, Kaplan E, Gale M, et al. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys 1992;24:17-23.
16. Resell R, Gomez-Codina J, Camps C, Maestre J, Padille J, Canto A, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-8.
17. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr., Lee JS, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-80.
18. The Lung Cancer Study Group. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988;6:9-17.
19. Eagan RT, Fleming TR, Schoonover V. Evaluation of response criteria in advanced lung cancer. Cancer 1979;44:1125-8.
20. National Cancer Institute Common Toxicity Criteria Guidelines. Bethesda, MD: National Cancer Institute, 1995.
21. Peto R, Peto J. Asymptotically efficient rank invariant test procedure. J Rad Stat Soc 1972;135:185-206.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
23. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988: 467-514.
24. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principle and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982:284-8.
26. Cox DR. Regression models and life tables (with discussion). J Rad Stat Soc 1972;34:187-220.
27. Stevens J. Multivariate statistical analysis for social and behavioral science. Hillsdale, NJ: Lawrence Erlbaum and Associates, 1996.
28. Peters LJ, Ang KK. The role of altered fractionation in head and neck cancers. Semin Radiat Oncol 1992;2:180-94.
29. Parsons JT, Mendenhall WM, Million RR, Cassisi NJ, Stringer SP. Twice-a-day irradiation of squamous cell carcinoma of the head and neck. Semin Radiat Oncol 1992;2:29-30.
30. Wang CC, Suit HD, Blitzer PH. Twice-a-day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys 1986;12:3-7.
31. Ang KK, Peters LJ. Concomitant boost radiotherapy in the treatment of head and neck cancers. Semin Radiat Oncol 1992;2:31-3.
32. Brindle JS, Shaw EG, Su JQ, Mailliard JA, Frank AR, Laurie JA, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage III non-small cell lung carcinoma. Cancer 1993;72:405-9.
33. Shaw EG, McGinnis WL, Jett JR, Su JQ. Frank AR, Mailliard JA, et al. Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst 1993;85:321-3.
34. Parsons JT, Mendenhall WM, Cassisi NJ, Isaacs JH Jr., Million RR. Hyperfractionation for head and neck cancer. Int J Radiat Oncol Biol Phys 1988;14:649-58.
35. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. RTOG 8808, ECOG 4588, preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up [abstract]. Int J Radiat Oncol Biol PhyS 1995;32(Suppl 1):195.
36. Saunders M, Barrett A. An interim report on the CHART randomized controlled trials in non-small cell carcinoma of the lung and squamous cell carcinoma of the head and neck [abstract]. Br J Cancer 1995;72(Suppl 25):2.
37. Sunders MI, Dische S, Barrett A, Parmar MK, Harvey A, Gibson D. Randomised multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer 1996;73:1455-62.
38. Saunders MI, Dische S. Randomised multicentre trial of CHART versus conventional radiotherapy in non-smal lung cancer: interim results and implications. Int J Radiat Oncol Biol Phys 1996;36(Suppl 1):208.